Leerink maintains Rocket Pharmaceuticals Market Perform, $4 target
Leerink Partners maintained a Market Perform rating on Rocket Pharmaceuticals and set a $4.00 price target, implying 61.3% upside versus the Oct 6 close of $2.48.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.